Do glucocorticoids affect the development of ulcers and erosions of the upper gastrointestinal tract in patients taking NSAIDs?
The use of glucocorticoids (GC) is considered one of the risk factors for the development of gastro-intestinal (GI) complications associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, the data on this issue are contradictory. Objective. To assess the frequency of ulcera...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2018-05-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/32748/pdf |
| Summary: | The use of glucocorticoids (GC) is considered one of the risk factors for the development of gastro-intestinal (GI) complications associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, the data on this issue are contradictory. Objective. To assess the frequency of ulceration and erosion in patients with rheumatic diseases (RD) receiving NSAIDs, depending on the concomitant use of GC. Materials and methods. A retrospective comparison was made of the incidence of gastrointestinal lesions detected in patients with RD during endoscopic examination in one medical center for 2007-2016. Three groups were formed: in group 1 patients took only NSAIDs (n=4823, women 80.7%, age 51.1 + 15.4 years), in group 2 patients took NSAIDs and GC (n = 1608, women 89, 8%, age 50.4 + 14.6 years), in group 3 - only patients took GC (n=1135, women 92.7%, age 44.1 + 15.3 years). The detection of multiple erosions (>10, ME) and gastric and / or duodenal ulcers was as-sessed. Results. The frequency of ME and ulcers in patients of groups 1 and 2 did not differ significantly: 10.5% and 8.5%, odds ratio 0.799 (95% confidence interval 0.546-1.169, p=0.072). Risk factors, such as age > 65 years, ulcer history and low-dose aspirin, did not affect this pattern. The incidence of ME and ulcers was significantly lower in Group 3 patients than in Groups 1 and 2: 6.3% (p |
|---|---|
| ISSN: | 0040-3660 2309-5342 |